VEGFR3 (FLT4) Antibody – Rabbit Polyclonal

Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Study of tumor angiogenesis has led to the identification of several proteins including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor. VEGF acts by interacting with a family of largely endothelial-specific receptor tyrosine kinases that includes VEGFR-1 (flt-1/flk-2), VEGFR-2 (flk- 1/KDR), and VEGFR-3/Flt-4. Disruption of VEGFRs interferes with differentiation of endothelial cells and it is lethal for the embryo. FLT-4 (mouse 1363aa and human 1298aa), a receptor protein tyrosine kinase, is a receptor for VEGF-C. Mouse FLT-4 protein topology: 1-24aa signal peptide, 25-1363 mature protein (25-775 EC domain, 776-797aa TM domain, 798-1363aa CP domain). FLT-4 is type 1 membrane protein. It is expressed in adult lung, and liver, and in fetal liver, brain, intestine, and placenta.

Small volumes of anti-FLT4 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS623912 is an antibody targeting FLT4. Also known as Anti-VEGFR3 (Vascular Endothelial Growth Factor Receptor 3, VEGFR-3, Fms-like Tyrosine Kinase 4, FLT-4, Tyrosine-protein Kinase Receptor FLT4, FLT4). Reactive in Human. Host: Rabbit.